| HOME >> BIOLOGY >> TECHNOLOGY |
GAITHERSBURG, Md. and CAPE TOWN, South Africa, Oct. 11 /PRNewswire-FirstCall/ -- Iomai Corporation (Nasdaq: IOMI) today announced that Iomai Chief Scientific Officer Gregory Glenn, M.D., presented an overview of the clinical data for Iomai's patch-based vaccine for travelers' diarrhea and the implications such a vaccine could have on global health at the Keystone Symposia: Challenges of Global Vaccine Development being held in Cape Town, South Africa.
Last month, Dr. Glenn presented data from a Phase 2 field study of the Iomai travelers' diarrhea vaccine that showed vaccinated travelers were 75 percent less likely to suffer clinically significant diarrhea and 84 percent less likely to suffer severe diarrhea. The company plans to begin Phase 3 studies next year.
The bacterial causes of travelers' diarrhea exact a toll not only on travelers, but also on those who live in areas in which those bacteria are endemic. Enterotoxigenic E. coli (ETEC) -- the most common cause of travelers' diarrhea -- has been linked to more than 200 million cases of diarrhea in infants and children living in the developing world each year, according to the World Health Organization, killing 380,000 annually.
"Diarrheal diseases are a top priority in global public health and we believe that our approach has the potential to save the lives of many of the world's most vulnerable: infants and children in the developing world," said Dr. Glenn. "The Bill and Melinda Gates Foundation has named acute diarrheal illness as one of its top funding priorities, and the non-profit group PATH is also working to use innovative solutions to limit the burden of diarrheal disease."
Dr. Glenn, the founder of Iomai, developed the company's p
'/>"/>
| SOURCE Iomai Corporation Copyright©2007 PR Newswire. All rights reserved |